# A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

> **NCT07705607** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1104 (estimated)

## Conditions studied

- Diabetic Retinopathy
- Macular Edema

## Interventions

- **DRUG:** MK-8748
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT07705607
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-25
- **Primary completion:** 2028-11-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 1104 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705607, "A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*